Denali Therapeutics Inc. $DNLI Shares Bought by Schroder Investment Management Group

Schroder Investment Management Group raised its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 32.5% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 386,539 shares of the company’s stock after buying an additional 94,744 shares during the period. Schroder Investment Management Group’s holdings in Denali Therapeutics were worth $5,408,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Caitong International Asset Management Co. Ltd grew its holdings in Denali Therapeutics by 277.0% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock worth $29,000 after acquiring an additional 1,551 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Denali Therapeutics in the 1st quarter worth approximately $41,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Denali Therapeutics by 15.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after purchasing an additional 753 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Denali Therapeutics by 120.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,236 shares of the company’s stock worth $115,000 after purchasing an additional 4,494 shares during the period. Finally, Entropy Technologies LP purchased a new position in shares of Denali Therapeutics during the 1st quarter valued at approximately $152,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Stock Up 5.8%

DNLI opened at $20.11 on Friday. The company has a market cap of $2.95 billion, a PE ratio of -6.91 and a beta of 1.11. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $26.18. The company has a 50-day moving average price of $16.56 and a 200 day moving average price of $15.08. The company has a quick ratio of 9.79, a current ratio of 9.79 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.02. During the same period last year, the firm earned ($0.63) earnings per share. The company’s revenue was up .0% on a year-over-year basis. Sell-side analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on DNLI shares. JPMorgan Chase & Co. increased their price target on shares of Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, October 8th. Morgan Stanley dropped their target price on Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, August 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Denali Therapeutics in a research note on Monday, September 8th. Finally, Stifel Nicolaus set a $37.00 price target on Denali Therapeutics in a report on Monday, November 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Denali Therapeutics currently has an average rating of “Buy” and a consensus target price of $32.64.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.